Skip to main content
Equibles

Michel Dahan

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Michel Dahan

Earlier roles on record: COO at Akebia Therapeutics, Inc. (AKBA) until March 22, 2024. Akebia Therapeutics, Inc. reported in an 8-K filed August 1, 2023 that Michel Dahan was terminated as Chief Operating Officer, effective March 22, 2024. The proxy statement of Akebia Therapeutics, Inc. reports total compensation of $1,212,463 for Michel Dahan in fiscal 2024, including a base salary of $251,850. Disclosed compensation is on record for 4 fiscal years.

“On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024 (the "Dahan July 2023 Amendment").”
Akebia Therapeutics, Inc. Form 8-K, filed August 1, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Akebia Therapeutics, Inc. (AKBA) $251,850 $1,212,463
2023 Akebia Therapeutics, Inc. (AKBA) $505,488 $1,245,374
2022 Akebia Therapeutics, Inc. (AKBA) $505,488 $1,287,386
2021 Akebia Therapeutics, Inc. (AKBA) $474,643 $1,267,970

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.